Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939090 · ClinicalTrials.gov registry record · Phase 3
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
A Phase 3 study of Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT04939090 is a Phase 3 study of Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 360 participants, above the 173-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (108% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04939090, a Phase 3 study of Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Olanzapine
- DRUG Megestrol Acetate
Study Locations (20)
California
- Epic Care-Dublin - Dublin
- Epic Care Partners in Cancer Care - Emeryville
- Washington Hospital - Fremont
- Contra Costa Regional Medical Center - Martinez
- Bay Area Tumor Institute - Oakland
- Zuckerberg San Francisco General Hospital - San Francisco
- Dominican Santa Cruz Hospital - Santa Cruz
- Epic Care Cyberknife Center - Walnut Creek
Arizona
- Arizona Center for Cancer Care - Gilbert - Gilbert
- CTCA at Western Regional Medical Center - Goodyear
- Arizona Center for Cancer Care-Peoria - Peoria
- Arizona Center for Cancer Care - Phoenix - Phoenix
- Arizona Center for Cancer Care - Osborn - Scottsdale
- Arizona Center for Cancer Care - Scottsdale - Scottsdale
- Arizona Center for Cancer Care-Surprise - Surprise
Colorado
- Rocky Mountain Cancer Centers-Aurora - Aurora
- Rocky Mountain Cancer Centers-Boulder - Boulder
- Rocky Mountain Cancer Centers - Centennial - Centennial
- Rocky Mountain Cancer Centers-Midtown - Denver
Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2022-01-03 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04939090
The ClinicalTrials.gov registry entry for NCT04939090 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 173-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (108% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT04939090 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT04939090 about?
NCT04939090 is a clinical study titled "Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients". This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the u...
What is the current status of trial NCT04939090?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2022-01-03. Estimated completion is 2027-12-31.
What conditions does trial NCT04939090 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Anorexia.
What interventions are being tested in trial NCT04939090?
The interventions under investigation include: Questionnaire Administration (OTHER), Olanzapine (DRUG), Megestrol Acetate (DRUG).
Who is sponsoring clinical trial NCT04939090?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04939090 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
RECRUITING · NA
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Advanced Malignant Solid Neoplasm
All registered trials for this condition
Hematopoietic and Lymphoid Cell Neoplasm
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.